1 / 5

Ph Morlat for the Groupe d’Epidémiologie Clinique du SIDA en Aquitaine (GECSA), Bordeaux, France

POSTER WEPDBO104. Antiretroviral drugs and incidence of chronic kidney disease, ANRS CO3 Aquitaine Cohort, France, 2004-2008. Ph Morlat for the Groupe d’Epidémiologie Clinique du SIDA en Aquitaine (GECSA), Bordeaux, France.

randy
Download Presentation

Ph Morlat for the Groupe d’Epidémiologie Clinique du SIDA en Aquitaine (GECSA), Bordeaux, France

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. POSTER WEPDBO104 Antiretroviral drugs and incidence of chronic kidney disease, ANRS CO3 Aquitaine Cohort, France, 2004-2008 Ph Morlat for the Groupe d’Epidémiologie Clinique du SIDA en Aquitaine (GECSA), Bordeaux, France

  2. CKD: emerging morbidity in HIV-infected pts (mainly treated in industrialized countries) Traditional risk factors, HIV-related factors, Role of ART ? ANRS CO3 Aquitaine Cohort - 2693 pts with CC > 60mL/min/1.73m2 (MDRD) - Median baseline CC: 90mL/min/1.73m2 - Mean follow-up (2004-2008): 3.4 years - ART treated: 95 % Mean cumulative ART exposure (since inclusion in the cohort): 7.6 years NRTI: 7.4y, tenofovir: 1.9y, NNRTI: 2.4y, PI: 3.6y.

  3. 86 pts progressed to CKD (defined as 2 consecutive CC< 60mL/min/1.73m2 ≥ 3 months apart) during 8477 PYFU. • Average incidence rate of CKD: 1.01% PYFU

  4. Impact of concomitant (>6 months) exposure to PIs/r? • Increase of TDF exposure (Kearney BP et al. J Acquir Immune Defic Syndr 2006) • Slower renal clearance of TDF(Kiser JJ et al. Clin Pharmacol Ther 2008) • Greater reduction of GFR (Fux CA et al. Antiv Therap 2007; Goicoechea M et al. J Infect Dis 2008) Use of tenofovir, mainly when co-administered with PIs, requires careful consideration when other risk factors of CKD are present (90% of pts developing CKD had ≥ 3 riskfactorsand 96% hadbaseline60<CC<90mL/min/1.73m2)

  5. Groupe d’Epidémiologie Clinique du SIDA en Aquitaine (GECSA), steering the ANRS CO3 Aquitaine Cohort: • Coordination: F. Dabis; Scientific committee: F. Bonnet, F. Dabis, M. Dupon, P. Mercié, P. Morlat, JL. Pellegrin, JM. Ragnaud; Epidemiology and Methodology: M. Bruyand, G. Chêne, F. Dabis, S. Lawson-Ayayi, R. Thiébaut; Infectious Diseases and Internal Medicine: M. Bonarek, F. Bonnal, F. Bonnet, N. Bernard, O. Caubet, L. Caunègre, C. Cazanave, J. Ceccaldi, I. Chossat, FA. Dauchy, C. De La Taille, S. De Witte, M. Dupon, P. Duffau, H. Dutronc, S. Farbos, Y. Gerard, C. Greib, D. Lacoste, P. Lataste, S. Lafarie, E. Lazaro, D. Malvy, P. Mercié, P. Morlat, D. Neau, A. Ochoa, JL. Pellegrin, T. Pistone, JM. Ragnaud, MC. Receveur, S. Tchamgoué, MA. Vandenhende, JF. Viallard; Immunology: P. Blanco, JF. Moreau, I. Pellegrin; Virology: H. Fleury, ME. Lafon, B. Masquelier. Pharmacology: D. Breilh; Drug monitoring: G. Miremont-Salamé; Data collection and processing: MJ. Blaizeau, M. Decoin, S. Delveaux, C. D’Ivernois, C. Hannapier, O. Leleux, B. Uwamaliya-Nziyumvira, X. Sicard; Computing and statistical analysis: S. Geffard, G. Palmer, D. Touchard. • The ANRS CO3 Aquitaine Cohort is supported in part by a grant from the Agence Nationale de recherches sur le SIDA et les Hépatites Virales (ANRS, Action Coordonnée no. 7, Cohortes)

More Related